Searchable abstracts of presentations at key conferences on calcified tissues

ba0006p132 | (1) | ICCBH2017

Anti-RANKL treatment in a murine model of fibrous dysplasia

Palmisano Biagio , Labella Rossella , Spica Emanuela , Remoli Cristina , Corsi Alessandro , Robey Pamela , Riminucci Mara

Fibrous dysplasia of bone (FD) is a crippling skeletal disease caused by activating mutations (R201C, R201H) of the Gsα gene. We recently generated GsαR201C transgenic mice that develop a FD skeletal phenotype. The analyses of these mice demonstrated that increased bone resorption is one of the main morbidity factors in FD and that RANKL is the major molecular mediator of osteolysis at affected skeletal sites.Ob...

ba0002oc21 | Miscellaneous | ICCBH2013

A randomized, double-blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone

Boyce Alison M , Kelly Marilyn H , Brillante Beth A , Kushner Harvey , Wientroub Shlomo , Riminucci Mara , Bianco Paolo , Robey Pamela G , Collins Michael T

Fibrous dysplasia (FD) is a benign skeletal disease caused by activating mutations of Gsα. These mutations lead to formation of abnormal and mechanically unsound bone and fibrotic tissue. Clinical sequelae include deformity, fracture, and pain. Studies in bisphosphonates have shown improvement in bone pain and inconsistent effects on FD mineralization; however interpretation has been limited by a lack of controlled trials.Objecti...

ba0007p150 | (1) | ICCBH2019

Osteogenesis imperfecta: skeletal outcomes after bisphosphonates discontinuation at final height

Robinson Marie-Eve , Trejo Pamela , Palomo Telma , Glorieux Francis H , Rauch Frank

Objectives: Intravenous cyclical bisphosphonates are widely used to treat children with moderate to severe osteogenesis imperfecta (OI). They increase bone mineral density (BMD), diminish fracture rates and improve mobility. Bisphosphonates are often discontinued when growth is completed. We aimed to determine if the skeletal gains achieved with bisphosphonates persist after their discontinuation in patients with OI.Methods: We assessed patients with OI ...

ba0005p155 | Cell biology: osteoblasts and bone formation | ECTS2016

L-Carnitine facilitates mitochondrial activity and osteogenic differentiation in human primary osteoblast culture

Vacante Fernanda , Montesano Anna , Spinello Alice , Bolamperti Simona , Senesi Pamela , Terruzzi Ileana , Luzi Livio , Villa Isabella , Rubinacci Alessandro

Osteoblasts have a high rate of energy consumption during bone formation and bone protein synthesis. Therefore, it is likely that decreased energy production that accompanies aging, could contribute to reduced osteoblast activity, a critical feature of senile osteoporosis, and that this reduction might be counteracted by favoring energy availability. Cells of the osteoblastic lineage generate 40–80% of the requested energy through fatty acid degradation, thus the modulati...

ba0005p157 | Cell biology: osteoblasts and bone formation | ECTS2016

Evidence for an osteogenic activity of betaine in human osteoblast in culture

Spinello Alice , Montesano Anna , Senesi Pamela , Villa Isabella , Bolamperti Simona , Vacante Fernanda , Luzi Livio , Rubinacci Alessandro , Terruzzi Ileana

Betaine (BET) is a component of many food. It is an essential osmolyte and a source of methyl groups. BET consumed from food sources and through dietary supplements presents similar bioavailability. BET exerts an antioxidant activity and decreases inflammation states. Dietary supplement with BET are used in many inflammation-connected pathologies, although its mechanism of action is not fully understood. Recent studies have shown that BET stimulates muscle fibers differentiati...